

# ACG/VGS/ODSGNA Regional Postgraduate Course

## Williamsburg, VA • September 7-8, 2019

---

### **Saturday, September 7, 2019**

#### **SESSION 1: UPPER GI**

Moderator: *Savita Srivastava, MD*

##### **Celiac Disease: Update on Management of Challenging Cases**

*Amy S. Oxentenko, MD, FACG*

Explain current challenges in the care of patients with gluten sensitivity and celiac disease, and outline treatment strategies for severe and refractory patients.

##### **Functional Dyspepsia: Getting to the Right Diagnosis and Treatment**

*William D. Chey, MD, FACG*

Identify the epidemiology, diagnostic processes, and best practices for the management of functional dyspepsia.

##### **Refractory GERD – Moving Beyond PPIs**

*David A. Leiman, MD*

Discuss diagnosis and treatment of refractory heartburn and chest pain resistant to PPI therapy.

#### **SESSION 2: PANCREAS / BILIARY**

Moderator: *Savita Srivastava, MD*

##### **Best Practices in EUS / FNA**

*Linda S. Lee, MD*

Define optimal techniques and practices in EUS/FNA to improve validity and quality, including the role of contrast-enhanced EUS, on-site cytopathology, needle types, and FNA versus FNB.

##### **Applying ACG Guidelines to Management of Pancreatic Cysts**

*Bryan G. Sauer, MD, MSc (Clin Res), FACG*

Recognize the types of pancreatic cysts, discuss diagnostic evaluation, and examine the varied guidelines for cyst management.

##### **Update on the Management of Necrotizing Pancreatitis**

*Amrita Sethi, MD*

Describe the approach used to manage patients with necrotizing pancreatitis, including the role of interventional endoscopy for management of complicated cases.

#### **SESSION 3: LIVER**

Moderator: *Savita Srivastava, MD*

##### **Non-Invasive Tests for Liver Fibrosis: Who, What, When, Where, Why, and How?**

*Richard K. Sterling, MD, MSc, FACG*

Identify the appropriate use of non-invasive liver fibrosis tests, such as serum fibrosis assays and imaging-based elastography, in clinical practice for patients with viral hepatitis, NASH, and other chronic liver disorders.

##### **Pearls and Pitfalls of Managing HCV Infection in Practice: Case-Based Learning**

*Patrick G. Northup, MD, FACG*

Using a case-based format, identify patient selection criteria for treatment with DAAs, pre-treatment counseling, insurance hurdles, selection of appropriate drug regimens, drug monitoring strategies, post-treatment surveillance, and options for treatment.

##### **Approach to Management of Solid and Cystic Liver Lesions in Non-Cirrhosis Patients**

*Fasiha Kanwal, MD, MSHS*

Explain the diagnosis and management of solid and cystic lesions of the liver found incidentally on standard GI imaging in non-cirrhosis patients.

## **Addressing the Epidemic of Burnout in Gastroenterology – Finding a Path to Physical and Psychological Wellbeing**

*Ronald J. Vender, MD, MACG*

Recognize and identify burnout predictors, describe what institutions or practices can do to mitigate burnout, and identify ways to facilitate work-life balance.

## **AFTERNOON BREAKOUT PRESENTATIONS**

### **Nursing Sponsored Session – Infection Prevention: A Primer on the SGNA Position Statements and Standards of Practice**

*Cynthia M. Friis, MEd, BSN, RN-BC*

Detail measures that can be taken to prevent infections in a GI practice.

### **ACG Legislative Update**

*Daniel J. Pambianco, MD, FACG*

Discuss the current political climate and policy priorities shaping the healthcare legislative process.

## **SESSION 4: LOWER GI / FUNCTIONAL**

Moderator: *Anne G. Tuskey, MD, FACG*

### **New Applications of the Microbiome in Clinical Practice: Beyond Recurrent *C. difficile***

*Jessica R. Allegretti, MD, MPH*

Evaluate the current understanding of the human microbiome and determine if we are able to test it, manipulate it, and apply our understanding to clinical practice.

### **CRC Screening: Consensus and Controversy in Special U.S. Populations**

*Aasma Shaukat, MD, MPH, FACG*

Analyze the current status of CRC prevention in the U.S., including screening options in special populations, strategies to improve screening participation, and recent changes in guidelines, such as earlier screening for African American patients and recent American Cancer Society guidelines for beginning screening for all populations at age 45.

### **SUDD and SCAD: New Entities in the Spectrum of Diverticular Disease – Recognition and Management**

*Brennan M. Spiegel, MD, MSHS, FACG*

Summarize new thinking about the role of antibiotics for acute diverticulitis and care of patients with symptomatic uncomplicated diverticular disease (SUDD) and segmental colitis associated with diverticular disease (SCAD).

## **SESSION 5: IBD**

Moderator: *Anne G. Tuskey, MD, FACG*

### **Update on Biologics and Novel Therapeutics in IBD**

*Aline Charabaty, MD*

Critically analyze the available data supporting biologics and novel therapeutics in IBD and provide guidance in choosing the appropriate treatment option in clinical practice.

### **Management of Perianal Disease**

*Susan Galandiuk, MD, FACG, FASCRS, FACS*

Describe the treatment options available for complicated perianal disease.

### **Pain Management in IBD**

*Laurie A. Keefer, PhD*

Recognize the impact of chronic pain in the management of IBD and outline effective treatment strategies to better manage pain.

**Sunday, September 8, 2019**

**SESSION 6: VGS-SPONSORED SYMPOSIUM: INNOVATION IN ENDOSCOPY**

Moderators: *Andrew Y. Wang, MD, FACP, and Tilak U. Shah, MD, MHS*

**Introduction to the Endoscopy Experience in Virginia Centers**

*Alvin M. Zfass, MD, MACG*

Discuss the beginnings and development of gastrointestinal endoscopy in Virginia and the role of the Virginia Gastroenterological Society in promoting the practice of endoscopy in Virginia and in the United States.

**Colorectal Lesion Assessment: Choosing the Best Therapeutic Approach**

*David A. Johnson, MD, MACG*

Describe endoscopic best practices regarding colorectal lesion assessment, in particular the Paris classification and dye-based and electronic chromoendoscopy classifications, and discuss features that might predict colorectal submucosal invasion and determine the appropriate intervention.

**Colorectal Resection – Tips for Optimal Polypectomy, Mucosal Resection, and Dissection**

*Tilak U. Shah, MD, MHS*

Identify the indications, risks, and techniques for endoscopic mucosal resection which may be useful to general gastroenterologists as well as to therapeutic endoscopists.

**Upper GI Lesions: Assessment and Resection**

*Andrew Y. Wang, MD, FACP*

Explain the endoscopic approach to assessing mucosally-derived neoplastic lesions in the esophagus, stomach, and duodenum and describe which types of endoscopic resection (EMR, ESD) are most applicable to certain lesions in the upper GI tract according to the location and lesion characteristics.

**State-of-the-Art Presentation: Submucosal, Extraluminal, and Full-Thickness Endoscopy: Where Does This Fit in GI and Who Should Be Doing It?**

*Amrita Sethi, MD*

Identify the forefront of endoscopic resection therapy and understand the benefits and pitfalls associated with submucosal, extraluminal, and full-thickness resection techniques.

**SESSION 7: OBESITY SYMPOSIUM**

Moderator: *Shelby A. Sullivan, MD, FACP*

**Dietary Approach in Medical Weight Loss**

*Shelby A. Sullivan, MD, FACP*

Discuss the rationale, pros, and cons of a variety of dietary weight loss options utilized in medical programs.

**Update on Pharmacologic Therapies in Weight Loss**

*Allan Hardy, MD*

Compare the currently available pharmacologic weight loss therapies, their indications, contraindications, and potential adverse effects.

**How to Manage NASH in the Obesity Epidemic**

*Zobair M. Younossi, MD, MPH, FACP*

Describe the best approach to distinguishing between patients with NAFLD, NASH, and advanced fibrosis, and treatment strategies used in a fatty liver clinic in 2019.

**Endoscopic Therapies for Obesity**

*Dilhana Badurdeen, MBBS, MD*

Recognize the various options for the endoscopic treatment of obesity, and the benefits and limitations of each.

**Does the Microbiome Influence Risk for Obesity?**

*Eamonn M. M. Quigley, MD, MACG*

Identify the role of the microbiome in obesity and weight loss resistance, along with treatment strategies under investigation.

**Practice Management: Pearls and Pitfalls in Setting Up Your GI Medical Weight Loss Clinic**

*Shelby A. Sullivan, MD, FACP*

Develop procedures and processes for a GI medical weight loss program, including the practice model, methods of delivering care, financial outlook, growth, ancillary services, and challenges in a procedure-driven GI environment.